Efficacy And Safety Of Ravulizumab In Older Patients Aged > 65 Years With Paroxysmal Nocturnal Hemoglobinuria In The 301 And 302 Phase 3 Extension Studies

R. Peffault De Latour,L. Mitchell,J. Szer,A. Kulasekararaj,J. S. Kim,C. Piatek,A. Kulagin,A. Hill,J. Wang,J. Yu,M. Ogawa,H. Schrezenmeier,J. W. Lee

BLOOD（2021）

引用 0|浏览26

暂无评分

摘要

Background: In the two largest phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH), ravulizumab given every 8 weeks was noninferior to eculizumab given every 2 weeks across all efficacy endpoints. Data on efficacy and safety of ravulizumab in patients aged >65 years with PNH are limited.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要